ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Pat…

ASH 2021 Conference Coverage on VuMedi

A. Perrot

D-Rd in Transplant-Ineligible NDMM: Results From the MAIA Trial

Laurent Garderet

Frontline Therapy for NDMM: The Role of Transplant, Duration & Goals…

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

A. Krishnan

SOHO Italy 2021: Newly Diagnosed Transplant-Eligible MM

SOHO 3rd Italian Conference

V. Montefusco

ASH 2021: Genomic and Immune Signatures Predict Sustained MRD Negati…

ASH 2021 Conference Coverage on VuMedi

E. Boyle

Treatment Updates for MM: Risk Stratification's Role in Upfront & Re…

Total Health

C. Gleason

Moffitt Cancer Center Debate: How Much Is Enough in NDMM - Triplet T…

Moffitt Cancer Center's 17th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

K. Shain

SOHO Italy 2021 on the Importance of Imaging in Novel Agents' Era in…

SOHO 3rd Italian Conference

E. Zamagni

Post-ASH Case Discussion: 59 y/o Male With Blurry Vision and Develop…

UChicago Medicine 7th Annual Updates from ASH 2021

S. Smith, M. Drazer

2021 ASH Updates in Smoldering Myeloma and Newly Diagnosed MM

Yale Cancer Center

E. Gorshein

Awareness Around MRD Testing in Myeloma: Why, When, and How to Test

Ola Landgren

High-Risk Myeloma: Failures and Future Directions

Rush University Medical Center

S. Usmani

EHA 2022 on a Phase III GMMG-HD7 Trial: Isa-RVd as Induction Therapy…

ecancer

E. Mai

ASCO 2022 on Moving Toward a Cure in Myeloma: The Role of MRD Testing

Nebraska Oncology Society

A. Nooka